 OUTLINE: This is a multicenter study. Patients are stratified according to disease risk group low risk beta-2 microglobulin and C-reactive protein 6 or either beta-2 microglobulin or C-reactive protein 6 vs high risk both beta-2 microglobulin and C-reactive protein 6. Patients are randomized to 1 of 2 treatment arms. 